InnoCom Bio Equities
Venture capitalSan Francisco · Pre-Seed–Series A · 9 people tracked
Investment thesis
The firm structures portfolio-based investments in life sciences technologies through special purpose vehicles, aiming to reduce risk via diversification across multiple technologies. It provides seed capital to innovators and founders, emphasizes early commercialization opportunities, and seeks to expedite value creation. The approach targets exclusive intellectual property with royalty and out-licensing potential, and works to create synergies by securing multiple technologies within a single portfolio.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website
Investments · 11 tracked
founders shown can be your intro pathFast-acting antimicrobial surface technology that eliminates 99.9% of bacteria, fungus, and viruses in under 2 minutes on high-touch surfaces.
MedTech appliance with 43 issued patents enabling comprehensive management of antibiotic-resistant infections and conventional wound care in human and animal health.
Plant-based biopharmaceutical production platform providing cost-effective, scalable biosimilar and biologics manufacturing using proprietary bioengineering technology.
Lung protein replacement therapy addressing deficiencies in respiratory conditions including COVID-19 sequelae, pneumonia, asthma, and COPD in humans and animals.
Repurposed drug therapy targeting orphan indications in Restrictive Cardiomyopathy with reduced regulatory pathway compared to traditional drug development.
Repurposed drug ESNtx005 targeting orphan indications in Restrictive Cardiomyopathy with superior efficacy demonstrated in historical clinical data.
realSKIN® biotherapeutic utilizing genetically engineered, pathogen-free porcine cells for live skin replacement with integrated vasculature, eliminating patient rejection.
Novel herpes virus platform engineered for safety, serving as viral vectors for HSV-1 prophylactic vaccine and HSV-2 therapeutic vaccine with UK fast-track designation.
Biotech company developing transformational drugs targeting aggressive ovarian and esophageal cancers with integrated biomarker identification systems.
Precision medicine platform delivering a first-in-class anti-solid tumor drug with composition patents in 32 countries, targeting both canine and human markets.
Haemoglobin-based oxygen carrier platform addressing severe blood loss and hemorrhagic shock in military, civilian, and veterinary trauma with significant federal contract funding.
Frequently asked questions
- What stage does InnoCom Bio Equities invest at?
- InnoCom Bio Equities invests at the Pre-Seed, Seed, Series A stages.
- What sectors does InnoCom Bio Equities focus on?
- InnoCom Bio Equities focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is InnoCom Bio Equities located?
- InnoCom Bio Equities is headquartered in San Francisco, US.
Images
Similar investors
Future Positive Capital is an investment firm backing entrepreneurs building companies that address major global challenges and shape more sustainable, preferable futures.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.